Table 3 Relation between the intensity of DDR1 and different parameters in carcinoma cases (n = 48)

Sex

Male

11 (50%)

5 (38.5%)

5 (38.5%)

Χ² = 0.645

0.724

Female

11 (50%)

8 (61.5%)

8 (61.5%)

Age (years)

Mean ± SD

53 ± 13.8

52.7 ± 11.2

58.5 ± 12.2

F = 0.920

0.394

Median (min.–max.)

58.5 (29–75)

55 (30–70)

60 (34 – 76)

Presence of polyps

Absent

21 (95.5%)

13 (100%)

12 (92.3%)

Χ² = 1.160

^MCp = 1.000

Present

1 (4.5%)

0 (0%)

1 (7.7%)

Adenoma

Absent

21 (95.5%)

13 (100%)

10 (76.9%)

Χ² = 3.981

^MCp = 0.148

Present

1 (4.5%)

0 (0%)

3 (23.1%)

Multiple tumors

Absent

22 (100%)

13 (100%)

11 (84.6%)

Χ² = 3.759

^MCp = 0.138

Present

0 (0%)

0 (0%)

2 (15.4%)

Gross description

Infiltrating

8 (36.4%)

3 (23.1%)

4 (30.8%)

Χ² = 3.792

^MCp = 0.448

Fungating

8 (36.4%)

9 (69.2%)

7 (53.8%)

Ulcerating

6 (27.3%)

1 (7.7%)

2 (15.4%)

Gross perforation

0

17 (77.3%)

11 (84.6%)

11 (84.6%)

Χ² = 0.434

^MCp = 0.804

1

5 (22.7%)

2 (15.4%)

2 (15.4%)

Grade

Low & intermediate

17 (77.3%)

11 (84.6%)

11 (84.6%)

Χ² = 0.434

^MCp = 0.808

High

5 (22.7%)

2 (15.4%)

2 (15.4%)

T stage

T2

2 (9.1%)

3 (23.1%)

2 (15.4%)

Χ² = 1.682

^MCp = 0.860

T3

15 (68.2%)

8 (61.5%)

8 (61.5%)

T4

5 (22.7%)

2 (15.4%)

3 (23.1%)

N stage

N0

10 (45.5%)

10 (76.9%)

8 (61.5%)

Χ² = 4.165

^MCp = 0.417

N1

8 (36.4%)

1 (7.7%)

3 (23.1%)

N2

4 (18.2%)

2 (15.4%)

2 (15.4%)

M stage

M0

17 (77.3%)

10 (76.9%)

9 (69.2%)

Χ² = 0.443

^MCp = 0.914

M1

5 (22.7%)

3 (23.1%)

4 (30.8%)

Modified Dukes’ staging

B

10 (45.5%)

9 (69.2%)

6 (46.2%)

Χ² = 10.031*

^MCp = 0.024^*

C

12 (54.5%)

3 (23.1%)

3 (23.1%)

D

0 (0%)

1 (7.7%)

4 (30.8%)

Combined Dukes’ staging

B, C

22 (100%)

12 (92.3%)

9 (69.2%)

Χ² = 7.150*

^MCp = 0.013^*

D

0 (0%)

1 (7.7%)

4 (30.8%)

Necrosis

Absent

16 (72.7%)

9 (69.2%)

10 (76.9%)

Χ² = 0.293

^MCp = 1.000

Present

6 (27.3%)

4 (30.8%)

3 (23.1%)

Apoptosis (n = 21)

Mean ± SD

26.3 ± 13.3

23.3 ± 23.1

26.1 ± 25.1

H = 0.181

0.914

Median (min.–max.)

25 (14–41)

17.5 (2–56)

20 (2–90)

Mitosis

Mean ± SD

8.8 ± 5.6

9.4 ± 6.5

10.4 ± 7.7

H = 0.159

0.924

Median (min.–max.)

8 (1–22)

8 (2–28)

10 (2–26)

n = 22

n = 13

n = 13

Vascular invasion

Absent

18 (81.81%)

11 (84.61%)

4 (30.76%)

Χ² = 12.00*

^MCp = 0.095

Present

4 (18.18%)

2 (15.38%)

9 (69.23%)

Lymph node harvest

Mean ± SD

13.5 ± 7.9

15.5 ± 8.1

15.5 ± 12.2

H = 0.782

0.676

Median (min.–max.)

11.5 (2–29)

14 (3–28)

13 (3–45)

Lymph node metastasis [N_ combined]

N0

21 (95.5%)

12 (92.3%)

8 (61.5%)

Χ² = 6.737*

^MCp = 0.028*

N1, 2

1 (4.5%)

1 (7.7%)

5 (38.5%)

Type of tumor/variant

Signet

0 (0%)

0 (0%)

3 (%)

Χ² = 13.776*

^MCp = 0.0080*

Adenocarcinoma

22 (100%)

12 (%)

7 (%)

Mucinous

Adenocarcinoma with mucinous differentiation

0 (0%)

0 (0%)

1 (%)

0 (0%)

2 (%)

1 (%)

Inflammatory response (n = 47)

Absent

0 (0%)

1 (7.7%)

6 (50.0%)

Χ² = 13.291*

^MCp < 0.001*

Present

22 (100%)

12 (92.3%)

6 (50%)

Tumor budding

Low (< 5)

10 (45.5%)

4 (30.8%)

8 (61.5%)

Χ² = 4.195

^MCp = 0.395

Intermediate (5–9)

8 (36.4%)

7 (53.8%)

5 (38.5%)

High (≥ 10)

4 (18.2%)

2 (15.4%)

0 (0%)

Recurrence

No

18 (81.8%)

10 (76.9%)

11 (84.6%)

Χ² = 0.398

^MCp = 1.000

Yes

4 (18.2%)

3 (23.1%)

2 (15.4%)

Death

No

10 (45.5%)

6 (46.2%)

8 (61.5%)

Χ² = 0.951

0.622

Yes

12 (54.5%)

7 (53.8%)

5 (38.5%)

Overall survival (n = 45)

Mean ± SD

17.2 ± 11.5

26.8 ± 13.1

13.7 ± 7.8

H = 8.398*

0.012*

Median (min.–max.)

15 (1–50)

27.5 (2–46)

14 (2–27)

Intensity of Epithelial β-catenin

Negative

4 (18.2%)

4 (30.8%)

7 (53.8%)

Χ² = 13.109*

^MCp = 0.025*

Mild

10 (45.5%)

4 (30.8%)

1 (7.7%)

Moderate

8 (36.4%)

2 (15.4%)

3 (23.1%)

Strong

0 (0%)

3 (23.1%)

2 (15.4%)